カレントテラピー　34-4　サンプル page 10/30

このページは カレントテラピー　34-4　サンプル の電子ブックに掲載されている10ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　34-4　サンプル

Current Therapy 2016 Vol.34 No.4 13総論325372：320-330, 20155）Weber JS, D’Angelo SP, Minor D, et al：Nivolumab versuschemotherapy in patients with advanced melanoma who progressedafter anti-CTLA-4 treatment（CheckMate 037）：arandomised, controlled, open -label, phase 3 trial. LancetOncol 16：375-384, 20156）Ribas A, Puzanov I, Dummer R, et al：Pembrolizumab versusinvestigator-choice chemotherapy for ipilimumab-refractorymelanoma（KEYNOTE -002）：a randomised, controlled,phase 2 trial. Lancet Oncol 16：908-918, 20157）Robert C, Ribas A, Wolchok JD, et al：Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma：a randomised dose-comparisoncohort of a phase 1 trial. Lancet 384：1109-1117, 20148）Robert C, Schachter J, Long GV, et al：Pembrolizumab versusIpilimumab in Advanced Melanoma. N Engl J Med 372：2521-2532, 20159）Atkins MB, Kudchadkar RR, Sznol M, et al：Phase 2, multicenter,safety and efficacy study of pidilizumab in patients withmetastatic melanoma. J Clin Oncol 32：suppl abstr 9001, 201410）Ribas A, Kefford R, Marshall MA, et al：Phase Ⅲ randomizedclinical trial comparing tremelimumab with standard-of-carechemotherapy in patients with advanced melanoma. J ClinOncol 31：616-622, 201311）Brahmer JR, Tykodi SS, Chow LQ, et al：Safety and activityof anti-PD-L1 antibody in patients with advanced cancer. NEngl J Med 366：2455-2465, 201212）Herbst RS, Soria JC, Kowanetz M, et al：Predictive correlatesof response to the anti-PD-L1 antibody MPDL3280A incancer patients. Nature 515：563-567, 201413）Sunshine J, Taube JM：PD-1/PD-L1 inhibitors. Curr OpinPharmacol 23：32-38, 201514）Webster RM：The immune checkpoint inhibitors：whereare we now? Nat Rev Drug Discov 13：883-884, 201415）Segal NH, Gopal AK, Bhatia S, et al：A phase 1 study ofPF-05082566（anti-4-1BB）in patients with advanced cancer.J Clin Oncol 32：suppl abstr 3007, 201416）Suntharalingam G, Perry MR, Ward S, et al：Cytokine stormin a phase 1 trial of the anti -CD28 monoclonal antibodyTGN1412. N Engl J Med 355：1018-1028, 200617）Quintana E, Shackleton M, Foster HR, et al：Phenotypic heterogeneityamong tumorigenic melanoma cells from patientsthat is reversible and not hierarchically organized. CancerCell 18：510-523, 201018）Alexandrov LB, Nik-Zainal S, Wedge DC, et al：Signaturesof mutational processes in human cancer. Nature 500：415-421, 201319）Larkin J, Chiarion -Sileni V, Gonzalez R, et al：CombinedNivolumab and Ipilimumab or Monotherapy in UntreatedMelanoma. N Engl J Med 373：23-34, 201520）Postow MA, Chesney J, Pavlick AC, et al：Nivolumab andipilimumab versus ipilimumab in untreated melanoma. NEngl J Med 372：2006-2017, 201521）Gnjatic S, Nishikawa H, Jungbluth AA, et al：NY-ESO-1：review of an immunogenic tumor antigen. Adv Cancer Res95：1-30, 200622）Le Gal FA, Ayyoub M, Dutoit V, et al：Distinct structuralTCR repertoires in naturally occurring versus vaccine -induced CD8＋ T-cell responses to the tumor-specific antigenNY-ESO-1. J Immunother 28：252-257, 200523）Tagliamonte M, Petrizzo A, Tornesello ML, et al：Antigenspecificvaccines for cancer treatment. Hum Vaccin Immunother10：3332-3346, 201424）Rosenberg SA, Yang JC, Restifo NP：Cancer immunotherapy：moving beyond current vaccines. Nat Med 10：909-915, 200425）Snyder A, Makarov V, Merghoub T, et al：Genetic basis forclinical response to CTLA-4 blockade in melanoma. N Engl JMed 371：2189-2199, 201426）Kreiter S, Vormehr M, van de Roemer N, et al：MutantMHC class Ⅱ epitopes drive therapeutic immune responsesto cancer. Nature 520：692-696, 201527）Schumacher T, Bunse L, Pusch S, et al：A vaccine targetingmutant IDH1 induces antitumour immunity. Nature 512：324-327, 201428）Yadav M, Jhunjhunwala S, Phung QT, et al：Predictingimmunogenic tumour mutations by combining mass spectrometryand exome sequencing. Nature 515：572-576, 201429）Boisguerin V, Castle JC, Loewer M, et al：Translation ofgenomics-guided RNA-based personalised cancer vaccines：towards the bedside. Br J Cancer 111：1469-1475, 201430）Fritsch EF, Hacohen N, Wu CJ：Personal neoantigen cancervaccines：The momentum builds. Oncoimmunology 3：e29311, 201431）Rosenberg SA, Restifo NP：Adoptive cell transfer as personalizedimmunotherapy for human cancer. Science 348：62-68, 201532）Rosenberg SA, Dudley ME：Adoptive cell therapy for thetreatment of patients with metastatic melanoma. Curr OpinImmunol 21：233-240, 200933）Schumacher TN, Schreiber RD：Neoantigens in cancerimmunotherapy. Science 348：69-74, 201534）Russell SJ, Peng KW, Bell JC：Oncolytic virotherapy. NatBiotechnol 30：658-670, 201235）Hu JC, Coffin RS, Davis CJ, et al：A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplexvirus expressing granulocyte macrophage colony-stimulatingfactor. Clin Cancer Res 12：6737-6747, 200636）Andtbacka RH, Kaufman HL, Collichio F, et al：TalimogeneLaherparepvec Improves Durable Response Rate in PatientsWith Advanced Melanoma. J Clin Oncol 33：2780-2788, 201537）Twyman-Saint Victor C, Rech AJ, Maity A, et al：Radiationand dual checkpoint blockade activate non -redundantimmune mechanisms in cancer. Nature 520：373-377, 201538）Sistigu A, Viaud S, Chaput N, et al：Immunomodulatoryeffects of cyclophosphamide and implementations for vaccinedesign. Semin Immunopathol 33：369-383, 201139）Mkrtichyan M, Najjar YG, Raulfs EC, et al：Anti-PD-1 synergizeswith cyclophosphamide to induce potent anti-tumorvaccine effects through novel mechanisms. Eur J Immunol41：2977-2986, 201140）Ott PA, Hodi FS, Robert C：CTLA -4 and PD -1/PD -L1blockade：new immunotherapeutic modalities with durableclinical benefit in melanoma patients. Clin Cancer Res 19：5300-5309, 201341）Schwarzenbach H, Hoon DS, Pantel K：Cell -free nucleicacids as biomarkers in cancer patients. Nat Rev Cancer 11：426-437, 2011